跳至主要内容
临床试验/NCT00838383
NCT00838383已完成2 期

SELECTIVE ENDOTHELIN TYPE A RECEPTOR INHIBITION IN CARDIAC SURGERY SUBJECTS WITH PRE-EXISTING CARDIOVASCULAR RISK FACTORS: A DOSE CONFIRMATION STUDY

Pfizer3 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2006年8月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Pfizer
入组人数
29
试验地点
3
主要终点
Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 0.5 Hour Post-separation From Cardiopulmonary Bypass (CPB)

研究概览

简要总结

This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require CPB.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
48 Years 至 82 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has been identified for coronary artery bypass grafting (CABG), aortic and/or mitral valve replacement, or combined CABG and cardiac valve replacement procedures that require cardiopulmonary bypass (CPB).

排除标准

  • Requires an emergent or "emergency" CABG and/or cardiac valve replacement.

研究组 & 干预措施

sitaxsentan (1.0 mg/kg)

Experimental

干预措施: sitaxsentan (Thelin) (Drug)

sitaxsentan (2.0 mg/kg)

Experimental

干预措施: sitaxsentan (Thelin) (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 0.5 Hour Post-separation From Cardiopulmonary Bypass (CPB)

时间窗: 0 hour, 0.5 hour post-separation from CPB

PVR in participants was derived from mean pulmonary artery pressure (PAP) (millimeter of mercury \[mmHg\]), pulmonary capillary wedge pressure (PCWP \[mmHg\]) and cardiac output (CO \[litres per minute\]). It was calculated using the following formula: (\[mean PAP-PCWP\] divided by CO)\*80, where CO= stroke volume (SV)\*heart rate (HR). Post-separation from CPB was the time immediately following cross-clamp release in CPB. Percent change in PVR at 0.5 hour post-separation from CPB in participants were summarized and reported.

Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 6 Hour Post-separation From Cardiopulmonary Bypass (CPB)

时间窗: 0 hour, 6 hour post-separation from CPB

PVR in participants was derived from mean PAP (mmHg), PCWP (mmHg) and CO (litres per minute). It was calculated using the following formula: (\[mean PAP-PCWP\] divided by CO)\*80, where CO= SV \* HR. Percent change in PVR at 6 hour in participants were summarized and reported.

Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 12 Hour Post-separation From Cardiopulmonary Bypass (CPB)

时间窗: 0 hour, 12 hour post-separation from CPB

PVR in participants was derived from mean PAP (mmHg), PCWP (mmHg) and CO (litres per minute). It was calculated using the following formula: (\[mean PAP-PCWP\] divided by CO)\*80, where CO= SV \* HR. Percent change in PVR at 12 hour in participants were summarized and reported.

Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 24 Hour Post-separation From Cardiopulmonary Bypass (CPB)

时间窗: 0 hour, 24 hour post-separation from CPB

PVR in participants was derived from mean PAP (mmHg), PCWP (mmHg) and CO (litres per minute). It was calculated using the following formula: (\[mean PAP-PCWP\] divided by CO)\*80, where CO= SV \* HR. Percent change in PVR at 24 hour in participants were summarized and reported.

Mortality: Number of Participants Died During Surgery and Initial Hospitalization

时间窗: During surgery, initial hospitalization period (up to 29 days for 1 mg/kg group, up to 44 days for 2 mg/kg dose group, up to 19 days for placebo group)

Number of participants who died during surgery or during initial hospitalization are reported here.

Number of Participants With Myocardial Infarction, Cerebrovascular Event, Hemodynamic Collapse and Re-operation

时间窗: Initial hospitalization period (up to 44 days)

Number of participants with following incidents: myocardial infarction (Q and non-Q wave); stroke or cerebrovascular event (acute ischemia, hemorrhagic stroke or infarction, or a transient ischemia attack); hemodynamic collapse (requiring ventricular assistance devices) and re-operation (participants who returned to the operating room) during the initial hospitalization were reported.

次要结局

  • Number of Participants With Inotropic Requirements During the 24 Hours Postoperative Period(Immediately after cross-clamp removal up to 24 hours post-separation from CPB)
  • Change From 0 Hour in Cardiac Output (CO) at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Central Venous Pressure (CVP) at 0.5, 6, 12, and 24 Hours Post-separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Hematocrit at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Heart Rate at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Mean Pulmonary Artery Pressure (MPAP) at 0.5, 6, 12, and 24 Hours Post-separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Pulmonary Capillary Wedge Pressure (PCWP) at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Venous Oxygen Saturation (SV02/02) at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Systemic Vascular Resistance (SVR) at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Mean Systemic Blood Pressure (MSBP) at 0.5, 6, 12, and 24 Hours Post-Separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Change From 0 Hour in Urine Output at 0.5, 6, 12, and 24 Hours Post-separation From Cardiopulmonary Bypass (CPB)(0, 0.5, 6, 12, 24 hours post-separation from CPB)
  • Number of Participants With Unanticipated Perioperative and Postoperative Blood Requirements(0 to 24 hours post-separation from CPB)
  • Duration of Assisted Ventilation(0 hour up to 24 hours post-separation from CPB)
  • Duration of Intensive Care Unit (ICU) Stay(0 hour post-separation from CPB up to 44 days)
  • Duration of Initial Postoperative Hospitalization(0 hour post-separation from CPB up to 44 days)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

终止
3 期
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term SafetyPulmonary Arterial HypertensionPulmonary Hypertension
NCT00796510Pfizer3
Enrolling By Invitation
2 期
Efficacy of Endothelin Receptor Antagonism in Coronary Artery SpasmCoronary Spasm
NCT06432452Radboud University Medical Center100
终止
3 期
A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT03809650Actelion9
进行中(未招募)
1 期
Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting - BQ-123 in CABGaorto-coronary bypass surgery in patients with coronary artery diseaseMedDRA version: 12.1Level: LLTClassification code 10011077Term: Coronary artery bypassMedDRA version: 12.1Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersMedDRA version: 12.1Level: LLTClassification code 10011090Term: Coronary artery surgeryMedDRA version: 12.1Level: LLTClassification code 10011098Term: Coronary bypassMedDRA version: 12.1Level: LLTClassification code 10049887Term: Coronary revascularisationMedDRA version: 12.1Level: LLTClassification code 10054366Term: Coronary revascularization
EUCTR2010-023552-90-ATMedizinische Universität Wien, Abteilung für Herzchirurgie36
进行中(未招募)
1 期
Efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled clinical trial. (EDIT-CAS)
CTIS2023-507782-25-00Stichting Radboud University Medical Center100